3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Terminated
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Sarcoma
1
NET
1
Lymphoid
1
Head & Neck
1
Gynecologic
1
Genitourinary
1
Gastrointestinal
1
Endocrine
1
Dermatologic
1
CNS
1
Breast
1
Conditions
Carcinoma, Non-Small-Cell Lung
10
Thyroid Neoplasms
2
Neoplasms
2
Brain Neoplasms
2
Urinary Bladder Neoplasms
1
Thyroid Cancer, Papillary
1
Thoracic Neoplasms
1
Sarcoma
1
Salivary Gland Neoplasms
1
Respiratory Tract Neoplasms
1
Respiratory Tract Diseases
1
Pancreatic Neoplasms
1
Ovarian Neoplasms
1
Neuroendocrine Tumors
1
Neoplasms, Unknown Primary
1
Neoplasms by Site
1
Melanoma
1
Lymphoma, Large-Cell, Anaplastic
1
Lung Neoplasms
1
Intestinal Neoplasms
1
Intestinal Diseases
1
Head and Neck Neoplasms
1
Gastrointestinal Neoplasms
1
Gastrointestinal Diseases
1
Digestive System Neoplasms
1
Digestive System Diseases
1
Colorectal Neoplasms
1
Colonic Diseases
1
Cholangiocarcinoma
1
Carcinoma, Renal Cell
1
Interventions
Magnetic Resonance Spectroscopy
5
lenvatinib
3
cabozantinib
3
Sunitinib
3
Iodine-131
3
trametinib
2
selpercatinib
2
dabrafenib
2
Sorafenib
2
Fluorodeoxyglucose F18
2
AZD 6244
2
2-phenyl-6-(2'-(4'-(ethoxycarbonyl)thiazolyl))thiazolo(3,2-b)(1,2,4)triazole
2
vandetanib
1
tremelimumab
1
tovorafenib
1
tanespimycin
1
romidepsin
1
pralsetinib
1
pembrolizumab
1
omipalisib
1
durvalumab
1
copanlisib
1
cediranib
1
alectinib
1
aflibercept
1
Vorinostat
1
Vemurafenib
1
Thyrotropin Alfa
1
Thyroidectomy
1
Thyroid (USP)
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Has results
×
Thyroid Cancer, Papillary
×
alectinib
×
Clear all
NCT04644315
2023-08-07
ALpha-T
Hoffmann-La Roche
Phase 2
Terminated
1 enrolled
5 charts